Keep testing new epitaphs. IPIX will keep testing new indications.
When your opponents have run out of legitimate argument and turn to Ad homonyms, victory is near.
GLTA (true) Longs. IPIX will succeed if the science proves out. Leo has out maneuvered those who would profit at the expense of millions in medical need. It’s down to clinical results.
Early and Mid-stage study results point toward B efficacy in multiple indications. We’re on the verge of final validation. Results, not blather, will write the IPIX story. (Additional studies funded by Gov’t playing catch-up are bonus.)
20/20, 2020!
Market Data 
Markets 
AI
